Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapy.

Jordan Randall Covvey, Blair Johnston, Fraser Wood, Anne Boyter

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The British guideline on the management of asthma produced by the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN) describes five steps for the management of chronic asthma. Combination therapy of a longacting β2-agonist (LABA) and an inhaled corticosteroid (ICS) is recommended as first-line therapy at step 3, although the dose of ICS at which to add a LABA is subject to debate.
To classify the inhaled therapy prescribed to patients with asthma in NHS Forth Valley according to two interpretations of the BTS/SIGN guideline and to evaluate the use of combination therapy in this population.
A retrospective analysis including patients from 46 general practitioner surgeries was conducted. Patients with physiciandiagnosed asthma were classified according to the BTS/SIGN guideline based on treatment prescribed during 2008. Patient characteristics were evaluated for the overall step classification, and specifically for therapy in step 3.
12,319 patients were included. Guideline interpretation resulted in a shift of 9.2% of patients (receiving medium-dose ICS alone) between steps 2 and 3. The largest proportion of patients (32.3%) was classified at step 4. Age, sex, smoking status, chronic obstructive pulmonary disease co-morbidity, and utilisation of short-acting β2-agonists and oral corticosteroids all correlated with step; however, no differences in these characteristics were evident between low-dose combination therapy and medium-dose ICS alone at step 3.
Further studies are needed to evaluate prescribing decisions in asthma. Guideline recommendations regarding the use of ICS dose escalation versus combination therapy need to be clarified relative to the published evidence.
LanguageEnglish
Pages290-295
Number of pages5
JournalPrimary Care Respiratory Journal
Volume22
Issue number3
DOIs
Publication statusPublished - 24 Jun 2013

Fingerprint

Thorax
Asthma
Databases
Guidelines
Adrenal Cortex Hormones
Therapeutics
General Practitioners
Chronic Obstructive Pulmonary Disease
Smoking
Morbidity
Population

Keywords

  • BTS/SIGN guideline
  • database analysis
  • retrospective
  • asthma therapy

Cite this

@article{35d2f8f850a6431ba8f2f0d740b56c73,
title = "Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapy.",
abstract = "The British guideline on the management of asthma produced by the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN) describes five steps for the management of chronic asthma. Combination therapy of a longacting β2-agonist (LABA) and an inhaled corticosteroid (ICS) is recommended as first-line therapy at step 3, although the dose of ICS at which to add a LABA is subject to debate. To classify the inhaled therapy prescribed to patients with asthma in NHS Forth Valley according to two interpretations of the BTS/SIGN guideline and to evaluate the use of combination therapy in this population. A retrospective analysis including patients from 46 general practitioner surgeries was conducted. Patients with physiciandiagnosed asthma were classified according to the BTS/SIGN guideline based on treatment prescribed during 2008. Patient characteristics were evaluated for the overall step classification, and specifically for therapy in step 3. 12,319 patients were included. Guideline interpretation resulted in a shift of 9.2{\%} of patients (receiving medium-dose ICS alone) between steps 2 and 3. The largest proportion of patients (32.3{\%}) was classified at step 4. Age, sex, smoking status, chronic obstructive pulmonary disease co-morbidity, and utilisation of short-acting β2-agonists and oral corticosteroids all correlated with step; however, no differences in these characteristics were evident between low-dose combination therapy and medium-dose ICS alone at step 3. Further studies are needed to evaluate prescribing decisions in asthma. Guideline recommendations regarding the use of ICS dose escalation versus combination therapy need to be clarified relative to the published evidence.",
keywords = "BTS/SIGN guideline, database analysis, retrospective, asthma therapy",
author = "Covvey, {Jordan Randall} and Blair Johnston and Fraser Wood and Anne Boyter",
year = "2013",
month = "6",
day = "24",
doi = "10.4104/pcrj.2013.00060",
language = "English",
volume = "22",
pages = "290--295",
journal = "Primary Care Respiratory Journal",
issn = "1471-4418",
number = "3",

}

Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapy. / Covvey, Jordan Randall; Johnston, Blair; Wood, Fraser; Boyter, Anne.

In: Primary Care Respiratory Journal, Vol. 22, No. 3, 24.06.2013, p. 290-295.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapy.

AU - Covvey, Jordan Randall

AU - Johnston, Blair

AU - Wood, Fraser

AU - Boyter, Anne

PY - 2013/6/24

Y1 - 2013/6/24

N2 - The British guideline on the management of asthma produced by the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN) describes five steps for the management of chronic asthma. Combination therapy of a longacting β2-agonist (LABA) and an inhaled corticosteroid (ICS) is recommended as first-line therapy at step 3, although the dose of ICS at which to add a LABA is subject to debate. To classify the inhaled therapy prescribed to patients with asthma in NHS Forth Valley according to two interpretations of the BTS/SIGN guideline and to evaluate the use of combination therapy in this population. A retrospective analysis including patients from 46 general practitioner surgeries was conducted. Patients with physiciandiagnosed asthma were classified according to the BTS/SIGN guideline based on treatment prescribed during 2008. Patient characteristics were evaluated for the overall step classification, and specifically for therapy in step 3. 12,319 patients were included. Guideline interpretation resulted in a shift of 9.2% of patients (receiving medium-dose ICS alone) between steps 2 and 3. The largest proportion of patients (32.3%) was classified at step 4. Age, sex, smoking status, chronic obstructive pulmonary disease co-morbidity, and utilisation of short-acting β2-agonists and oral corticosteroids all correlated with step; however, no differences in these characteristics were evident between low-dose combination therapy and medium-dose ICS alone at step 3. Further studies are needed to evaluate prescribing decisions in asthma. Guideline recommendations regarding the use of ICS dose escalation versus combination therapy need to be clarified relative to the published evidence.

AB - The British guideline on the management of asthma produced by the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN) describes five steps for the management of chronic asthma. Combination therapy of a longacting β2-agonist (LABA) and an inhaled corticosteroid (ICS) is recommended as first-line therapy at step 3, although the dose of ICS at which to add a LABA is subject to debate. To classify the inhaled therapy prescribed to patients with asthma in NHS Forth Valley according to two interpretations of the BTS/SIGN guideline and to evaluate the use of combination therapy in this population. A retrospective analysis including patients from 46 general practitioner surgeries was conducted. Patients with physiciandiagnosed asthma were classified according to the BTS/SIGN guideline based on treatment prescribed during 2008. Patient characteristics were evaluated for the overall step classification, and specifically for therapy in step 3. 12,319 patients were included. Guideline interpretation resulted in a shift of 9.2% of patients (receiving medium-dose ICS alone) between steps 2 and 3. The largest proportion of patients (32.3%) was classified at step 4. Age, sex, smoking status, chronic obstructive pulmonary disease co-morbidity, and utilisation of short-acting β2-agonists and oral corticosteroids all correlated with step; however, no differences in these characteristics were evident between low-dose combination therapy and medium-dose ICS alone at step 3. Further studies are needed to evaluate prescribing decisions in asthma. Guideline recommendations regarding the use of ICS dose escalation versus combination therapy need to be clarified relative to the published evidence.

KW - BTS/SIGN guideline

KW - database analysis

KW - retrospective

KW - asthma therapy

U2 - 10.4104/pcrj.2013.00060

DO - 10.4104/pcrj.2013.00060

M3 - Article

VL - 22

SP - 290

EP - 295

JO - Primary Care Respiratory Journal

T2 - Primary Care Respiratory Journal

JF - Primary Care Respiratory Journal

SN - 1471-4418

IS - 3

ER -